NASDAQ:MXCT MaxCyte Q1 2025 Earnings Report $2.55 -0.10 (-3.77%) As of 04:00 PM Eastern Earnings HistoryForecast MaxCyte EPS ResultsActual EPSN/AConsensus EPS -$0.10Beat/MissN/AOne Year Ago EPSN/AMaxCyte Revenue ResultsActual RevenueN/AExpected Revenue$9.05 millionBeat/MissN/AYoY Revenue GrowthN/AMaxCyte Announcement DetailsQuarterQ1 2025Date5/7/2025TimeAfter Market ClosesConference Call DateWednesday, May 7, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads MaxCyte Earnings HeadlinesMaxCyte intends to delist from London's AIM to enhance liquidityApril 15 at 5:24 PM | lse.co.ukMaxCyte to Delist from AIM, Focus on NasdaqApril 15 at 2:14 AM | tipranks.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 16, 2025 | Colonial Metals (Ad)MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comWith 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsApril 8, 2025 | uk.finance.yahoo.comSee More MaxCyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MaxCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MaxCyte and other key companies, straight to your email. Email Address About MaxCyteMaxCyte (NASDAQ:MXCT), a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.View MaxCyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s Next Upcoming Earnings Netflix (4/17/2025)American Express (4/17/2025)Blackstone (4/17/2025)Infosys (4/17/2025)Marsh & McLennan Companies (4/17/2025)Charles Schwab (4/17/2025)Taiwan Semiconductor Manufacturing (4/17/2025)UnitedHealth Group (4/17/2025)HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
